Generic-drug maker also developing specialty drugs for Parkinson's disease and other conditions.
Generic-drug maker also developing specialty drugs for Parkinson's disease and other conditions.
Sells most products to three big drug wholesalers that supply US pharmacies, so a few buyers set terms on generics, where price competition is intense. To offset that, it has been adding branded specialty drugs, such as Crexont, approved in 2024, and biosimilars, copies of biologic medicines, from partners.
Moat: narrow (scale, cost advantage). Vertically integrated US generics manufacturing scale, with a smaller specialty franchise for differentiation.
Headquarters: Bridgewater, New Jersey, United States · Founded: 2002 · Employees: 8,500
Size Amneal Pharmaceuticals (AMRX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $7.62B, the 907th largest of 3,085 United States companies the cockpit tracks. Shares closed at $21.88 on 18 Nov 2026.
Performance Over six months the shares gained 78.9%, against -0.4% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 8.9% over the last twelve months (peer median +13.9%); the operating margin is 16.4% (peer median 13.8%).
Valuation It trades at 19.2× forward earnings against a peer median of 21.9× (8th cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 17% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.2 points above its cost of capital (9.6% WACC).
Short interest Short interest is 3.3% of the free float (30 Oct 2026).
Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $3.20B | $3.02B | $2.79B | $2.39B | $2.21B |
| Revenue growth | — | +8% | +17% | +8% | — |
| Gross profit | $1.29B | $1.14B | $1.02B | $857M | $796M |
| EBITDA | $719M | $647M | $589M | $492M | $441M |
| Net income | $133M | $72.1M | -$117M | -$84.0M | -$130M |
| Free cash flow | $30.9M | $241M | $235M | $136M | $14.6M |
| Capital expenditure | $242M | $114M | $75.0M | $69.2M | $90.6M |
| Total debt | $3.28B | $2.69B | $2.59B | $2.75B | $2.85B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals AMRX | $7.62B | +79% | +9% | 16% | 19.2× | 17.2% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.3B | +23% | -4% | 19% | 15.0× | 10.5% |
| Viatris VTRS | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% |
| Amphastar Pharmaceuticals AMPH | $1.27B | +64% | +3% | 19% | 9.1× | 2.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AMRX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +10.3% | +1.7% | 6th highest of 21 |
| 6-month return | +78.9% | -0.4% | highest of 21 |
| Distance from 52-week high | -1.1% | -13.9% | highest of 21 |
| Revenue growth (TTM) | +8.9% | +13.9% | 9th lowest of 21 |
| Operating margin | 16.4% | 13.8% | 9th highest of 20 |
| Forward P/E | 19.2× | 21.9× | 8th cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 17.2% | 7.3% | 6th most demanding of 14 |
| Growth delivered (Del g) | +8.7% | +9.4% | 6th lowest of 14 |
| Hurdle (Req g minus delivered) | +8.5 pp | -3.7 pp | 4th most demanding of 14 |
| ROIC minus cost of capital | +1.2 pp | +1.7 pp | 8th lowest of 19 |
| EV / EBITDA | 15.1× | 23.1× | 4th cheapest of 12 |
| Net debt / EBITDA | 4.3× | -0.3× | 3rd most indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals AMRX | United States | $7.62B | +79% | +9% | 16% | 19.2× | 17.2% | +8.7% |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | China | $7.57B | -14% | +8% | 6% | 14.8× | 2.9% | +6.6% |
| Grifols GRF.MC | Spain | $7.48B | +19% | +1% | 16% | 13.1× | 7.1% | +7.1% |
| Kiniksa Pharmaceuticals International KNSA | United States | $7.47B | +75% | +58% | 14% | 56.6× | 10.4% | +45.5% |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 15.3× | 23.9% | +16.6% |
| Alkermes Public ALKS | United States | $7.87B | +27% | +15% | 5% | n/a | 32.5% | +7.3% |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |
| ALK-abello A/S ALK-B.CO | Denmark | $7.94B | -8% | +16% | 26% | 34.8× | 7.3% | +12.6% |
| Glenmark Pharmaceuticals GLENMARK.NS | India | $7.98B | +10% | 0% | 17% | 33.1× | 27.3% | +9.4% |
| Asymchem Laboratories (Tianjin) 002821.SZ | China | $7.27B | +20% | +18% | 17% | 37.4× | n/a | n/a |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | n/a | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | n/a | n/a | n/a |
| Shanghai Pharmaceuticals 601607.SS | China | $8.23B | 0% | +4% | 3% | 11.2× | -10.1% | +8.1% |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
| Rhythm Pharmaceuticals RYTM | United States | $8.25B | +31% | +61% | -67% | n/a | n/a | n/a |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| Protagonist Therapeutics PTGX | United States | $8.30B | +26% | +164% | 59% | 1,532.5× | 17.5% | +10.0% |
| Kyowa Kirin 4151.T | Japan | $8.43B | +9% | +10% | 24% | 16.4× | -4.7% | +9.3% |
| Praxis Precision Medicines PRAX | United States | $8.53B | -9% | -100% | n/a | n/a | n/a | n/a |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% | +5.3% |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% | +10.7% |